Page 23 - 73_01

VOL. 73 (1), 5-26, 2007 IN VITRO INVESTIGATION OF DRUG METABOLISM AND TOXICITY...

(49) WIENKERS, L. C. and HEATH, T. G. (2005): Predicting in vivo drug interactions
(50) from in vitro drug discovery data. Nat. Rev. Drug Discov. 4: 825-833.
CURI-PEDROSA, R.; DAUJAT, M.; PICHARD, L.; OURLIN, L. C.; CLAIR, P.; GERVOT, L.;
(51) LESCA, P.; DOMERGUE, J.; JOYEUX, H.; FOURTANIER, G. and MAUREL, P. (1994):
(52) Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A
(53) in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269: 384-
(54) 392.
MASUBUCHI, N.; LI, A. P. and OKAZAKI, O. (1998): An evaluation of the
(55) cytochrome P450 induction potential of pantoprazole in primary human
(56) hepatocytes. Chem-Biol Interact. 114: 1-13.
PELKONEN, O.; HUKKANEN, J.; HONKAKOSKI, P.; HAKKOLA, J.; VIITALA, P. and RAUNIO,
(57) H. (2002): In Ernst Schering Res Found Workshop 37 (Pelkonen, O. and
Baumann, A. Eds.) pp. 105-137.
(58) WAXMAN, D. J. (1999): P450 gene induction by structurally diverse
(59) xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch.
(60) Biochem. Biophys. 369: 11-23.
(61) RONIS, M. J. J.; HUANG, J.; CROUCH, J.; MERCADO, C.; IRBY, D.; VALENTINE, C. R.;
LUMPKIN, C. K.; INGELMAN-SUNDBERG, M. and BADGER, T. M. (1993): Cytochrome
(62) P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-
step mechanism associated with blood alcohol concentrations in rats. J.
Pharmacol. Exp. Ther. 264: 944-950.
Whitlock, J. P. (1999): Induction of cytochrome P4501A1. Annu. Rev.
Pharmacol. Toxicol. 39: 103-125.
MCGEHEE, R. E.; RONIS, M. J. J.; COWHERD, R. M.; INGELMAN-SUNDBERG, M. and
BADGER, T. M. (1994): Characterization of cytochrome P450 2E1 induction in
a rat hepatoma FGC-4 cell model by ethanol. Biochem Pharmacol. 48: 1823-
1833.
JONES, S. A.; MOORE, L. B.; SHENK, J. L.; WISELY, G. B.; HAMILTON, G. A.; MCKEE,
D. D.; TOMKINSON, N. C.; LECLUYSE, E. L.; LAMBERT, M. H.; WILLSON, T. M.;
KLIEWER, S. A. and MOORE, J. T. (2000): The pregnane X receptor: a
promiscuous xenobiotic receptor that has diverged during evolution. Mol.
Endocrinol. 14: 27-39.
LI, A. P. (2001): Screening for human ADME/Tox drug properties in drug
discovery. Drug Discov Today. 6: 357-366.
MILLER, M. S.; MCCARVER, D. G.; BELL, D. A.; EATON, D. L. and GOLDSTEIN, J.
A. (1997): Genetic polymorphisms in human drug metabolic enzymes.
Fundam. Appl. Toxicol. 40: 1-14.
GÓMEZ-LECHÓN, M. J.; DONATO, M. T.; CASTELL, J. V. and JOVER, R. (2003):
Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr
Drug Metab. 4: 292-312.
NIEMINEN, A. L.; SAYLOR, A. K.; TESFAI, S. A.; HERMAN, B. and LEMASTERS, J. J.
(1995): Contribution of the mitochondrial permeability transition to lethal
injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem. J. 307:
99-106.
ROSS, D. (1989) Mechanistic toxicology: a radical perspective. J. Pharm.
Pharmacol. 41: 505-511.

25